focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Share News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 3.00 (13.043%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 24.50
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Elixirr meets guidance, in strong start to 2023

Mon, 27th Feb 2023 10:37

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Elixirr International PLC, up 20% at 503.0 pence, 12-month range 412p-780p. The consultancy firm says 2022 was a strong year, with all metrics to be "in line or above" market expectations. Revenue is expected to rise 40% to GBP70.7 million, within previous guidance, and adjusted earnings before interest, tax, depreciation and amortisation is expected at GBP20.4 million - which is in line with Elixirr's guidance of exceeding GBP20 million. Says 2023 has started "strongly" with an acceleration of organic growth in the first quarter, and January seeing record monthly revenue.

----------

Directa Plus PLC, up 10% at 87p, 12-month range 76p-87p. The graphene nanoplatelet products producer and supplier says revenue in 2022 is now expected at not less than EUR10.8 million, which is up from EUR10.0 million communicated back in December's trading update. This represents a 25% increase year-on-year. Says momentum has continued into 2023, with trading meeting market expectations, which Directa cites as revenue of EUR13.5 million for the year.

----------

AIM - LOSERS

----------

Hercules Site Services PLC, down 38% at 44.99p, 12-month range 40p-73p. The labour supply company for the UK infrastructure sector raises GBP1.7 million in a placing of 3.8 million shares at issue price of 45p - which represents a 24% discount to Friday's closing price of 59p. "With a strong 2023 pipeline in place, these funds will support further organic growth in our Labour Supply division, which represented over 67% of our revenue in 2022," says Chief Executive Brusk Korkmaz.

----------

Oncimmune Holdings PLC, down 23% at 42p, 12-month range 36.69p-146.0p. The immuno-diagnostics developer says, in the 15 months to August 31, revenue was GBP3.8 million, little changed from GBP3.7 million in the year to May 31. Pretax loss widens to GBP11.6 million from GBP6.1 million across the same time frame. However, says revenue in the first six months of financial 2023 are expected to exceed GBP3.8 million, and it expects to be operating cashflow positive during the year.

----------

Forward Partners Group PLC, down 6.5% at 36p, 12-month range 35p-98.4p. The early-stage technology-focused investor says the fair value of its portfolio fell 40% to no less than GBP79.0 million at December 31, from GBP117.1 million a year before. Net asset value per share is expected to plunge to 71.0p from 104p a year before. The investment firm blamed valuation headwinds, "due to public market and macroeconomic pressures". "Despite the pressure on valuations many of them still grew rapidly," says Chief Executive Nic Brisbourne.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
15 Dec 2020 22:00

UK TRADING UPDATE SUMMARY: Triple Point Social Ups Credit Facility

UK TRADING UPDATE SUMMARY: Triple Point Social Ups Credit Facility

Read more
14 Dec 2020 22:04

UK TRADING UPDATE SUMMARY: Novacyt Unveils New Test For Mink Covid

UK TRADING UPDATE SUMMARY: Novacyt Unveils New Test For Mink Covid

Read more
14 Dec 2020 14:54

Oncimmune signs two NHS contracts, has NICE guidance published

(Sharecast News) - Oncimmune has signed a commercial contract to supply its 'EarlyCDT Lung' blood test to NHS Norfolk & Waveney Clinical Commissioning Group, it announced on Monday.

Read more
16 Nov 2020 16:03

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
11 Nov 2020 20:17

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

Read more
11 Nov 2020 10:13

Oncimmune enters deal with Augmenta to profile plasma samples

(Sharecast News) - Immunodiagnostics group Oncimmune has signed a new master service agreement with Augmenta Bioworks, it announced on Wednesday, to profile patient plasma samples and characterise therapeutic candidates discovered through Augmenta's 'SingleCyte' and 'DeepGrid' discovery platforms.

Read more
30 Oct 2020 14:53

IN BRIEF: Oncimmune Annual Loss Widens As Expenses Climb

IN BRIEF: Oncimmune Annual Loss Widens As Expenses Climb

Read more
28 Oct 2020 17:43

UK TRADING UPDATE SUMMARY: Shoe Zone Ends Financial Year On Back Foot

UK TRADING UPDATE SUMMARY: Shoe Zone Ends Financial Year On Back Foot

Read more
13 Oct 2020 17:59

IN BRIEF: Oncimmune In Covid Antibody Profiling Deal With Cedars-Sinai

IN BRIEF: Oncimmune In Covid Antibody Profiling Deal With Cedars-Sinai

Read more
6 Oct 2020 19:28

UK TRADING UPDATE SUMMARY: Petra Strikes Deal With South African Union

UK TRADING UPDATE SUMMARY: Petra Strikes Deal With South African Union

Read more
6 Oct 2020 13:54

Oncimmune granted funding for Covid-19 research collaboration

(Sharecast News) - Immunodiagnostics company Oncimmune Holdings announced the award of funding from UK Research and Innovation's (UKRI) 'Ideas to Address Covid-19' programme on Tuesday.

Read more
23 Sep 2020 19:09

UK TRADING UPDATE SUMMARY: Joules In Lockdown Hit But Online Surges

UK TRADING UPDATE SUMMARY: Joules In Lockdown Hit But Online Surges

Read more
23 Sep 2020 16:05

Oncimmune enters collaboration with Roche subsidiary

(Sharecast News) - Immunodiagnostics group Oncimmune Holdings has signed a collaboration with Roche subsidiary Genentech, it announced on Wednesday, to characterise the autoantibody profiles of patients in clinical trials for rheumatological diseases, including systemic lupus erythematosus (SLE).

Read more
3 Sep 2020 20:34

IN BRIEF: Oncimmune Notes Publication Of Study Assessing EarlyCDT Lung

IN BRIEF: Oncimmune Notes Publication Of Study Assessing EarlyCDT Lung

Read more
2 Sep 2020 16:06

IN BRIEF: Oncimmune Signs Autoantibody Profiling Programme Agreement

IN BRIEF: Oncimmune Signs Autoantibody Profiling Programme Agreement

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.